Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis

Evolve Trial Investigators · New England Journal of Medicine · 2012 · 947 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +17

Clinical Practice Guideline for the Management of Chronic Kidney Disease‐Mineral and Bone Disorder

Masafumi Fukagawa, Keitaro Yokoyama, Fumihiko Koiwa et al. · Therapeutic Apheresis and Dialysis · 2013 · 397 citations · Full text

Medicine, Endocrinology, Nephrology +17

Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism

Geoffrey A. Block, David A. Bushinsky, Sunfa Cheng et al. · JAMA · 2017 · 304 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Recent Changes in Therapeutic Approaches and Association with Outcomes among Patients with Secondary Hyperparathyroidism on Chronic Hemodialysis

Francesca Tentori, Mia Wang, Brian Bieber et al. · Clinical Journal of the American Society of Nephrology · 2014 · 278 citations

Medicine, Nephrology, Pharmacotherapy +17

Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favourable control of the serum phosphorus and calcium levels in Japanese dialysis patients

Masafumi Fukagawa, S. Yumita, Tadao Akizawa et al. · Nephrology Dialysis Transplantation · 2007 · 143 citations · Full text

Medicine, Nephrology, Pharmacology +14